Add this topic to your myFT Digest for news straight to your inbox
If these stock moves can be called a correction, it is a minor one
Tax reform and tech earnings send S&P 500 to its best one-day gain in almost a year
AbbVie’s 9% tax rate reveals how law is a boon companies that keep their IP overseas
Most of the biggest names in the field say they are committed to fighting the disease
Tie-up with Alector to explore whether immune system can halt destruction of brain cells
Trump’s failure to overhaul American tax code takes toll on M&A
World’s second-biggest pharmaceuticals company aims to become leading player in oncology
Ian Read says case for drugmaker’s break-up has become ‘more complicated’ in recent months
Makers of medicines with $22bn sales a year expected to fight hard to delay rivals’ introduction
Pharma groups unveil encouraging research that fuels hopes for patients who have run out of options
US groups ready to move after raising more than $50bn in debt this year
Delegates at world’s largest gathering of oncologists to address how to help more victims
Cash-rich corporates are in the vanguard
Abbott, AbbVie and Sanofi announce separate purchases, taking 2016 transactions to $121bn
Cancer biotech agreement comes as drugmaker tries to reduce reliance on blockbuster medicine
International Edition